{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:43:42Z","timestamp":1792269822999,"version":"4.4.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:00:00Z","timestamp":1792195200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:00:00Z","timestamp":1792195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-026-01646-0","type":"journal-article","created":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:04:41Z","timestamp":1792224281000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Final analysis results from DREAMM-3, a phase 3 study of belantamab mafodotin versus pomalidomide plus dexamethasone in patients with relapsed\/refractory multiple myeloma"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-3254","authenticated-orcid":false,"given":"Meletios Athanasios","family":"Dimopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4327-1957","authenticated-orcid":false,"given":"Vania","family":"Hungria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atanas","family":"Radinoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4549-0694","authenticated-orcid":false,"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sosana","family":"Delimpasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabor","family":"Mikala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2322-9863","authenticated-orcid":false,"given":"Tamas","family":"Masszi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5224-1979","authenticated-orcid":false,"given":"Marcelo","family":"Capra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Low","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0140-9548","authenticated-orcid":false,"given":"Angelo","family":"Maiolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6167-3319","authenticated-orcid":false,"given":"Yan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9822-4170","authenticated-orcid":false,"given":"Xavier","family":"Leleu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0421-9424","authenticated-orcid":false,"given":"Vasiliki","family":"Pappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Chraniuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Konstantinova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iurii","family":"Osipov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn","family":"Hakim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Brawley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Tubel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"McKeown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Boyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumita","family":"Roy-Ghanta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9422-6614","authenticated-orcid":false,"given":"Katja","family":"Weisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,17]]},"reference":[{"key":"1646_CR1","doi-asserted-by":"crossref","unstructured":"Watson EC, Shuwa HA, Heycock M, Wade J, Wang C-Y, Htun M, et al. Belantamab Mafodotin Triggers Immune Invigoration in Multiple Myeloma Via Inflammatory and Immunogenic Cell Death. medRxiv. 2025:2025.09.11.25335116.","DOI":"10.1101\/2025.09.11.25335116"},{"key":"1646_CR2","first-page":"665","volume":"111","author":"H Musa","year":"2026","unstructured":"Musa H, Mielnik M, Trudel S, Weisel K, Mockus-Daehn T, Ferron-Brady G, et al. Belantamab mafodotin does not induce B-cell maturation antigen loss or systemic immune dysfunction in multiple myeloma. Haematologica. 2026;111:665\u201378.","journal-title":"Haematologica"},{"key":"1646_CR3","doi-asserted-by":"publisher","first-page":"4629","DOI":"10.1158\/1078-0432.CCR-22-0618","volume":"28","author":"AC Baines","year":"2022","unstructured":"Baines AC, Ershler R, Kanapuru B, Xu Q, Shen G, Li L, et al. FDA Approval Summary: Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma. Clin Cancer Res. 2022;28:4629\u201333.","journal-title":"Clin Cancer Res"},{"key":"1646_CR4","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/onco.13592","volume":"26","author":"K Tzogani","year":"2021","unstructured":"Tzogani K, Penttil\u00e4 K, L\u00e4hteenvuo J, Lapvetel\u00e4inen T, Lopez Anglada L, Prieto C, et al. EMA review of Belantamab Mafodotin (Blenrep) for the treatment of adult patients with relapsed\/refractory multiple myeloma. Oncologist. 2021;26:70\u20136.","journal-title":"Oncologist"},{"key":"1646_CR5","unstructured":"U.S. Food and Drug Administration. FDA granted accelerated approval to belantamab mafodotin-blmf for multiple myeloma. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-granted-accelerated-approval-belantamab-mafodotin-blmf-multiple-myeloma. Accessed 4 Sep 2025."},{"key":"1646_CR6","unstructured":"European Medicines Agency. EMA recommends non-renewal of authorisation of multiple myeloma medicine Blenrep. https:\/\/www.ema.europa.eu\/en\/news\/ema-recommends-non-renewal-authorisation-multiple-myeloma-medicine-blenrep. Accessed 4 Sep 2025."},{"key":"1646_CR7","doi-asserted-by":"publisher","first-page":"e801","DOI":"10.1016\/S2352-3026(23)00243-0","volume":"10","author":"MA Dimopoulos","year":"2023","unstructured":"Dimopoulos MA, Hungria VTM, Radinoff A, Delimpasi S, Mikala G, Masszi T, et al. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study. Lancet Haematol. 2023;10:e801\u2013e12.","journal-title":"Lancet Haematol"},{"key":"1646_CR8","unstructured":"European Medicines Agency. BLENREP Summary of Product Characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/blenrep-epar-product-information_en.pdf. Accessed 25 June 2026."},{"key":"1646_CR9","unstructured":"U.S. Food and Drug Administration. BLENREP highlights of the prescribing information. 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761440s000lbl.pdf. Accessed 25 June 2026."},{"key":"1646_CR10","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa2403407","volume":"391","author":"MA Dimopoulos","year":"2024","unstructured":"Dimopoulos MA, Beksac M, Pour L, Delimpasi S, Vorobyev V, Quach H, et al. Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma. N Engl J Med. 2024;391:408\u201321.","journal-title":"N Engl J Med"},{"key":"1646_CR11","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/S1470-2045(25)00330-4","volume":"26","author":"V Hungria","year":"2025","unstructured":"Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, et al. Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial. Lancet Oncol. 2025;26:1067\u201380.","journal-title":"Lancet Oncol"},{"key":"1646_CR12","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1158\/1535-7163.MCT-21-0035","volume":"20","author":"R Montes de Oca","year":"2021","unstructured":"Montes de Oca R, Alavi AS, Vitali N, Bhattacharya S, Blackwell C, Patel K, et al. Belantamab Mafodotin (GSK2857916) drives immunogenic cell death and immune-mediated antitumor responses in vivo. Mol Cancer Ther. 2021;20:1941\u201355.","journal-title":"Mol Cancer Ther"},{"key":"1646_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01212-0","volume":"15","author":"P Mukhopadhyay","year":"2025","unstructured":"Mukhopadhyay P, Abdullah HA, Opalinska JB, Paka P, Richards E, Weisel K, et al. The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development. Blood Cancer J. 2025;15:15.","journal-title":"Blood Cancer J"},{"key":"1646_CR14","doi-asserted-by":"publisher","first-page":"5708","DOI":"10.1182\/bloodadvances.2025016949","volume":"9","author":"M-V Mateos","year":"2025","unstructured":"Mateos M-V, Trudel S, Quach H, Robak P, Beksac M, Pour L, et al. Modification of Belantamab Mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 Trials. Blood Adv. 2025;9:5708\u201319.","journal-title":"Blood Adv"},{"key":"1646_CR15","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1002\/cncr.34987","volume":"129","author":"AK Nooka","year":"2023","unstructured":"Nooka AK, Cohen AD, Lee HC, Badros A, Suvannasankha A, Callander N, et al. Single-agent belantamab mafodotin in patients with relapsed\/refractory multiple myeloma: Final analysis of the DREAMM-2 trial. Cancer. 2023;129:3746\u201360.","journal-title":"Cancer"},{"key":"1646_CR16","doi-asserted-by":"publisher","first-page":"3357","DOI":"10.1182\/blood-2023-178009","volume":"142","author":"VTM Hungria","year":"2023","unstructured":"Hungria VTM, Weisel K, Radinoff A, Delimpasi S, Mikala G, Masszi T, et al. Impact of long-term treatment with belantamab mafodotin on safety and efficacy outcomes in patients with relapsed\/refractory multiple myeloma in DREAMM-3. Blood. 2023;142:3357.","journal-title":"Blood"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01646-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01646-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01646-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:03:05Z","timestamp":1792267385000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01646-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,17]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1646"],"URL":"https:\/\/doi.org\/10.1038\/s41408-026-01646-0","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,17]]},"assertion":[{"value":"5 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Meletios Athanasios Dimopoulos has served as a consultant, received honoraria from, and was involved in speaker\u2019s bureaus or advisory committees for Amgen, Sanofi, Regeneron, Menarini, Takeda Pharmaceuticals, GSK, BMS, Janssen, Beigene, Swixx Biopharma, and AstraZeneca, and has had travel expenses covered by Amgen, BMS, Janssen, and Takeda. Vania Hungria has received honoraria from AbbVie, Amgen, BMS, Celgene, GSK, J&J, Roche, Sanofi, and Takeda. Haitao Meng has no conflicts to report. Atanas Radinoff has received honoraria from Roche, Pfizer, AbbVie, Swixx, SOBI, and Novartis; consulting or advisory fees from Roche, Swixx, and SOBI. Jian Li has no conflicts to report. Sosana Delimpasi has received honoraria from Amgen, GSK, Janssen, and Takeda. Ting Niu has no conflicts to report. Gabor Mikala has received honoraria from AbbVie, Amgen, Celgene, Janssen, BMS, Takeda, Roche, and Richter; has received consulting or advisory fees from AbbVie, Amgen, Celgene, Janssen, BMS, Takeda, Roche; research funding from AbbVie; and fees for travel, accommodations, and expenses from BMS, Janssen, and Takeda. Tamas Masszi has received fees for participation on a Data Safety Monitoring Board or Advisory Board from AbbVie, BMS, Janssen, Novartis, Pfizer, and Takeda. Marcelo Capra has received speaker\u2019s bureau participation fees from Sanofi, BMS, and Janssen, and fees for travel, accommodations, and expenses from Sanofi, BMS, and Janssen. Michael Low has no conflicts to report. Angelo Maiolino reports honoraria from Amgen, BMS, Janssen, Sanofi, and Takeda. Yan Xu has no conflicts to report. Xavier Leleu has received honoraria from Amgen, BMS\/Celgene, Janssen, Takeda, Novartis, Sanofi, Merck, Oncopeptide, Karyopharm, Roche, AbbVie, Carsgen, GSK, and Harpoon Therapeutics. Vasiliki Pappa reports research funding from Genesis Pharma SA. Dominik Chraniuk has no conflicts to report. Tatiana Konstantinova has no conflicts to report. Iurii Osipov has no conflicts to report. Shawn Hakim is an employee of and holds financial equities in GSK, and holds stock options in Pfizer. Chris Brawley is an employee of and holds financial equities in GSK. Gabriela Tubel is an employee of and holds financial equities in GSK. Astrid McKeown is an employee of GSK and holds financial equities in GSK, AstraZeneca, and Novartis. Julia Boyle is an employee of GSK and holds financial equities in GSK. Sumita Roy-Ghanta is an employee of GSK and holds financial equities in GSK. Katja Weisel has received honoraria from Abbvie, Amgen, Adaptive Biotech, Astra Zeneca, BMS\/Celgene, Janssen, GSK, Karyopharm, Novartis, Oncopeptides, Pfizer, Roche Pharma, Sanofi, Stemline, and Takeda; consulting or advisory fees from Abbvie, Amgen, Adaptive Biotech, BMS\/Celgene, Janssen, GSK, Karyopharm, Oncopeptides, Pfizer, Roche Pharma, Sanofi, and Takeda; and research funding from Abbvie, Amgen, BMS\/Celgene, Janssen, GSK, and Sanofi.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"184"}}